Fennec Pharmaceuticals
FENC
56 hedge funds and large institutions have $125M invested in Fennec Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 17 closing their positions.
207% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $362K
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
15% more capital invested
Capital invested by funds: $108M → $125M (+$16M)
6% more funds holding
Funds holding: 53 → 56 (+3)
4.02% more ownership
Funds ownership: 49.31% → 53.34% (+4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| 1 |
BlackRock
New York
|
+$6.47M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.17M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.56M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.47M |
| 5 |
SCM
Solas Capital Management
Darien,
Connecticut
|
+$1.28M |
Top Sellers
FENC Hedge Fund Activity: Q2 2023 in Review
56 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q2 2023, worth a combined $125M — up 15% from $108M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new FENC positions and 17 closed out — a net gain of 3 holders — while 18 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $6.47M. The largest seller was DG Capital Management, cutting an estimated $1.46M.
- 56 institutional investors held Fennec Pharmaceuticals (FENC) as of Q2 2023, up from 53 in Q1 2023.
- Funds reported $125M of Fennec Pharmaceuticals stock for Q2 2023, up 15% quarter-over-quarter.
- 20 funds opened new Fennec Pharmaceuticals positions in Q2 2023 and 17 closed out, a net change of +3 holders.
- The largest Fennec Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $6.47M added.
- The largest Fennec Pharmaceuticals seller in Q2 2023 was DG Capital Management, an estimated $1.46M sold.
Based on aggregated 13F filings for Q2 2023.